Headache News and Research RSS Feed - Headache News and Research

In medicine a headache or cephalalgia is a symptom of a number of different conditions of the head. Some of the causes are benign while others are medical emergencies.
Further Reading

Researchers identify new Chinese herbal medicine that inhibits hepatitis C virus activity

Data from a late-breaking abstract presented at the International Liver CongressTM 2014 identifies a new compound, SBEL1, that has the ability to inhibit hepatitis C virus (HCV) activity in cells at several points in the virus' lifecycle. [More]
Longer looks: Vermont's single payer system; Nevada's cancer cluster; the toll of dementia on a family

Longer looks: Vermont's single payer system; Nevada's cancer cluster; the toll of dementia on a family

Skatchewan is a vast prairie province in the middle of Canada. It's home to hockey great Gordie Howe and the world's first curling museum. But Canadians know it for another reason: it's the birthplace of the country's single-payer health-care system. [More]
Ironwood and Forest commence new DTC patient awareness campaign for LINZESS

Ironwood and Forest commence new DTC patient awareness campaign for LINZESS

awareness campaign for LINZESS, a once-daily treatment for adults with irritable bowel syndrome with constipation or chronic idiopathic constipation. [More]

Gilead Sciences announces positive results from LDV/SOF phase 2 studies on HCV infection

Gilead Sciences, Inc. (Nasdaq: GILD) today announced data from two Phase 2 studies evaluating investigational all-oral regimens containing the nucleotide analog polymerase inhibitor sofosbuvir (SOF) for the treatment of chronic hepatitis C virus (HCV) infection. [More]

Scientists working on new blood test to diagnose stroke faster

When someone suffers from a stroke, a silent countdown begins. A fast diagnosis and treatment can mean the difference between life and death. So scientists are working on a new blood test that one day could rapidly confirm whether someone is having a stroke and what kind. Their report appears in the ACS journal Analytical Chemistry. [More]
Alkermes announces results from phase 3 clinical trial of aripiprazole lauroxil in patients with schizophrenia

Alkermes announces results from phase 3 clinical trial of aripiprazole lauroxil in patients with schizophrenia

Alkermes plc today announced positive topline results from a randomized, double-blind, placebo-controlled phase 3 clinical trial of aripiprazole lauroxil in patients with schizophrenia. Patients treated once monthly with either 441 mg or 882 mg of aripiprazole lauroxil demonstrated statistically significant reductions from baseline in Positive and Negative Syndrome Scale (PANSS) total scores at week 12, compared to placebo (p<0.001 aripiprazole lauroxil 441 mg, p<0.001 aripiprazole lauroxil 882 mg), which was the prespecified primary endpoint in the study. Based on the positive results from this phase 3 study, Alkermes plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the third quarter of 2014. [More]
Astellas, Medivation submit European Marketing Authorization Application for XTANDI capsules

Astellas, Medivation submit European Marketing Authorization Application for XTANDI capsules

Astellas Pharma Inc. and Medivation Inc. today announced the submission of a variation to amend the European Marketing Authorization Application for XTANDI® (enzalutamide) capsules for the treatment of adult men with metastatic castration-resistant prostate cancer (mCRPC) who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy and in whom chemotherapy is not yet clinically indicated. [More]

ER physicians discount early signs of strokes among women, minorities, younger people

Analyzing federal health care data, a team of researchers led by a Johns Hopkins specialist concluded that doctors overlook or discount the early signs of potentially disabling strokes in tens of thousands of American each year, a large number of them visitors to emergency rooms complaining of dizziness or headaches. [More]

Doctors overlook early signs of strokes in people each year

Analyzing federal health care data, a team of researchers led by a Johns Hopkins specialist concluded that doctors overlook or discount the early signs of potentially disabling strokes in tens of thousands of American each year, a large number of them visitors to emergency rooms complaining of dizziness or headaches. [More]
Researchers identify possible way to prevent headaches of climbers

Researchers identify possible way to prevent headaches of climbers

By monitoring blood flow in the brains of six climbers scaling Mount Kilimanjaro in Tanzania, German medical researchers have identified a possible way to prevent the headaches that are a common feature of altitude sickness. This work appears in the latest issue of JNIRS—Journal of Near Infrared Spectroscopy. [More]
Gilead reports topline results from sofosbuvir Phase 3 trial in Japan for treatment of HCV infection

Gilead reports topline results from sofosbuvir Phase 3 trial in Japan for treatment of HCV infection

Gilead Sciences, Inc. today announced topline results from a Phase 3 clinical trial (Study GS-US-334-0118) in Japan evaluating the once-daily nucleotide analog polymerase inhibitor sofosbuvir in combination with ribavirin (RBV) for the treatment of genotype 2 chronic hepatitis C virus (HCV) infection. [More]
Frail elderly people are at increased risk of death from outbreaks of viral gastroenteritis

Frail elderly people are at increased risk of death from outbreaks of viral gastroenteritis

Frail elderly people living in residential care facilities are at increased risk of severe illness or death from outbreaks of viral gastroenteritis. [More]
FDA expands age indication of Adacel vaccine for immunization against tetanus, diphtheria, pertussis

FDA expands age indication of Adacel vaccine for immunization against tetanus, diphtheria, pertussis

Sanofi Pasteur, the vaccines division of Sanofi, announced today that the U.S. Food and Drug Administration (FDA) has expanded the approved age indication of Adacel® (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed; Tdap) for active booster immunization for the prevention of tetanus, diphtheria, and pertussis as a single dose in persons 10 through 64 years of age. [More]

Looking forward: How to judge the rollout; challenges to come

Following the official end of the enrollment season, some outlets turn their attention to the upcoming issues surrounding the law. [More]
UT Southwestern launches telemedicine program to extend stroke care to patients in rural areas

UT Southwestern launches telemedicine program to extend stroke care to patients in rural areas

UT Southwestern Medical Center has launched a state-of-the-art telemedicine program that will extend immediate access to UT Southwestern's nationally recognized stroke care during the crucial time period when treatment is needed for a patient of an ischemic stroke, or clot in one of the brain's blood vessels. [More]
Amgen reports positive findings from AMG 145 Phase 3 studies in patients at risk for cardiovascular disease

Amgen reports positive findings from AMG 145 Phase 3 studies in patients at risk for cardiovascular disease

Amgen (NASDAQ: AMGN) today announced new detailed data from three Phase 3 studies that showed treatment with its novel investigational cholesterol-lowering medication, evolocumab (AMG 145), resulted in a statistically significant reduction of 55-66 percent in low-density lipoprotein cholesterol (LDL-C) compared to placebo in patients with high cholesterol. [More]
Biogen Idec's ALPROLIX receives FDA approval for hemophilia B treatment

Biogen Idec's ALPROLIX receives FDA approval for hemophilia B treatment

Today Biogen Idec announced that the U.S. Food and Drug Administration has approved ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], the first recombinant, DNA derived hemophilia B therapy with prolonged circulation in the body. [More]

States work to clarify enrollment rules, untangle technical problems as open enrollment period moves toward its close

News outlets also report that states are still conducting outreach efforts and offering the latest tallies of people who are signing up as well as information about subsidies. [More]

First Edition: March 28, 2014

The White House said on Thursday that more than six million people had signed up for medical insurance plans under President Obama's health care law, exceeding the administration's revised goal for enrollment by the Monday deadline. [More]
CDC identifies six new cases of people with Heartland virus

CDC identifies six new cases of people with Heartland virus

The Centers for Disease Control and Prevention in collaboration with health officials in Missouri and Tennessee have identified six new cases of people sick with Heartland virus: five in Missouri and one in Tennessee. The new cases, discovered in 2012 and 2013, are described today in CDC's Morbidity and Mortality Weekly Report. [More]